InvestorsHub Logo
Followers 3
Posts 210
Boards Moderated 0
Alias Born 06/03/2020

Re: None

Sunday, 09/12/2021 10:06:28 AM

Sunday, September 12, 2021 10:06:28 AM

Post# of 43835
More than 37.6% Shorted but PPS Up 1.2%!!

It seems that the desperate shorts are having a very hard time with all their manipulations. On Friday, again a high amount of 37.6% of the daily traded shares (as reported by FINRA) have been shorted — but the PPS went up 1.2% (up 24.11% over the last month)!! This led to the total short interest of 8.9 million shares (21.5% of the float)!! With all the facts and clarifications that we got in the latest Letter to Shareholders and the information nicely summarised in the fact sheet below (see link), it should just be a matter of time until Multikine will be approved by the FDA and the heavy manipulation by the shorts will come to an end (just wait until we get some real volume) after all those years they have been attacking Cel-Sci. Once the shorts will start to cover their 8.9 million shares, we are going to witness the most EPIC SHORT SQUEEZE! I am so happy for all the cancer patients who will soon be able to profit from Multikine! GLTAL!!

In the most recent BioTech CEO interview, Geert Kersten talks about Multikine:

"We figured we could make at least 12,000 or 13,000 treatments a year. And we looked at it in terms of dollars, that's close to two billion dollars. Guys, we have the existing facility. So what we have is we have created a drug, the likes of which never the world has never seen. It should become part of the standard of care, one of the two arms of head and neck cancer. That's 210,000 people. No safety issues. It's a big deal. We've done a ten year study, that’s the largest ever in head and neck cancer, one of the biggest cancers in the world. We're the first in the world to show benefit from using a cancer drug before surgery and radiation. We built our manufacturing facility before phase 3 and doubled its capacity over the past year."

"It is becoming clear to me that there are financial reasons for others that just don't want us to succeed. The concept of a new, non-toxic cancer drug is something no one has done before. We believe it's all about helping people, and we believe that the FDA will see it the same way."

https://cel-sci.com/wp-content/uploads/2021/07/CVM_FactSheet_website_072021.pdf
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CVM News